Skip to main content
SpringerLink
Log in

The role of tumor board conferences in neuro-oncology: a nationwide provider survey

  • Topic Review
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The tumor board or multidisciplinary cancer meeting (MCM) is the foundation of high value multidisciplinary oncology care, coordinating teams of specialists. Little is known on how these meetings are implemented in Neuro-oncology. Benefits of MCMs include coordination, direction for complicated cases, education, and a forum for communication, emerging technology, and clinical trials. This study identifies participation and utilization of neuro-oncology MCMs. A cross-sectional descriptive survey was dispersed through an internet questionnaire. The Society of Neuro-Oncology and the American Brain Tumor Association provided a list of dedicated neuro-oncology centers. All National Cancer Institute designated centers, and participants in the Adult Brain Tumor Consortium or the Brain Tumor Trials Collaborative were included, identifying 85 centers. Discussion included primary brain tumors (100%), challenging cases (98%), recurrent disease (96%), neoplastic spine disease (93%), metastatic brain lesions (89%), pre-surgical cases (82%), pathology (76%), and paraneoplastic disease (40%). MCMs were composed of neuro-oncologists, neurosurgeons, and radiation oncologists (100%), radiologists (98%), pathologists (96%), and clinical trial participants (64%). Individual preparation ranged from 15 to 300 min. MCMs were valued for clinical decision making (94%), education (89%), and access to clinical trials (69%). 13% documented MCMs in the medical record. 38% of centers used a molecular tumor board; however, many commented with uncertainty as to how this is defined. Neuro-oncology MCMs at leading U.S. institutions demonstrate congruity of core disciplines, cases discussed, and perceived value. We identified variability in preparation time and implementation of MCM recommendations. There is high uncertainty as to the definition and application of a molecular tumor board.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. El Saghir NS, Charara RN, Kreidieh FY, Eaton V, Litvin K, Farhat RA, Khoury KE, Breidy J, Tamim H, Eid TA (2015) Global practice and efficiency of multidisciplinary tumor boards: results of an American Society of Clinical Oncology international survey. J Glob Oncol 1(2):57–64

    Article  Google Scholar 

  2. NCI Dictionary of Cancer Terms (2016). Natl Cancer Inst. http://www.cancer.gov/publications/dictionaries/cancer-terms. Accessed 08 Dec 2016

  3. NCI Healthcare Teams Initiative (2016). Natl Cancer Inst. http://healthcaredelivery.cancer.gov/healthcare/. Accessed 08 Dec 2016

  4. ASCO-ESMO (2006) ASCO-ESMO consensus statement on quality cancer care. Ann Oncol 17(7):1063–1064

    Article  Google Scholar 

  5. Merkow RP, Chung JW, Paruch JL, Bentrem DJ, Bilimori KY (2014) Relationship between cancer center accreditation and performance on publicly reported quality measures. Ann Surg 259(6):1091–1097

    Article  PubMed  Google Scholar 

  6. Cancer Program Standards (2016) Am Coll Surg. https://www.facs.org/quality-programs/cancer/coc/standards. Accessed 08 Dec 2016

  7. Charara RN, Kreidieh FY, Farhat RA, et al (2016) Practice and impact of multidisciplinary tumor boards on patient management: a prospective study. J Glob Oncol. doi:10.1200/JGO.2016.004960 (Abstract)

    Google Scholar 

  8. Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N (2011) Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Ann Surg Oncol 18(8):2116–2125

    Article  PubMed  Google Scholar 

  9. Scher KS, Tisnado DM, Rose DE, Adams JL, Ko CY, Malin JL, Ganz PA, Kahn KL (2011) Physician and practice characteristics influencing tumor board attendance: results from the provider survey of the Los Angeles Women’s Health Study. J Oncol Pract 7(2):103–110

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lamb BW, Sevdalis N, Arora S, Pinto A, Vincent C, Green JS (2011) Teamwork and team decision-making at multidisciplinary cancer conferences: barriers, facilitators, and opportunities for improvement. World J Surg 35(9):1970–1976

    Article  PubMed  Google Scholar 

  11. El Saghir NS, Keating NL, Carlson RW, Khoury KE, Fallowfield L (2014) Tumor boards: optimizing the structure and improving efficiency of multidisciplinary management of patients with cancer worldwide. Am Soc Clin Oncol Educ Book e461–466

  12. Fennell ML, Das IP, Clauser S, Petrelli N, Salner A (2010) The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr 2010(40):72–80

    Article  PubMed  PubMed Central  Google Scholar 

  13. Ruhstaller T, Roe H, Thürlimann B, Nicoll JJ (2006) The multidisciplinary meeting: an indispensable aid to communication between different specialities. Eur J Cancer 42(15):2459–2462

    Article  PubMed  Google Scholar 

  14. American Society of Clinical Oncology (2014) The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract 10(2):119–142

    Article  Google Scholar 

  15. Kuroki L, Stuckey A, Hirway P, Raker CA, Bandera CA, DiSilvestro PA, Grannai CO, Legare RD, Sakr BJ, Dizon DS (2010) Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women’s cancer program. Gynecol Oncol 116(3):295–300

    Article  PubMed  Google Scholar 

  16. Newman EA, Guest AB, Helvie MA, Roubidoux MA, Chang AE, Kleer OG, Diehl KM, Cimmino VM, Pierce L, Hayes D, Newman LA, Sabel MS (2006) Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer 107(10):2346–2351

    Article  PubMed  Google Scholar 

  17. Kesson EM, Allardice GM, George WD, Burns HJ, Morrison DS (2012) Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13,722 women. BMJ 344:e2718

    Article  PubMed  PubMed Central  Google Scholar 

  18. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Shulman LN, McNeil BJ (2013) Tumor boards and the quality of cancer care. J Natl Cancer Inst 105(23):113–121

    Article  PubMed  PubMed Central  Google Scholar 

  19. Taplin SH, Weaver S, Salas E, Cholette V, Edwards HM, Bruinooge SS, Kosty MP (2015) Reviewing cancer care team effectiveness. J Oncol Pract Am Soc Clin Oncol 11(3):239–246

    Article  Google Scholar 

  20. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381

    Article  PubMed  Google Scholar 

  21. Pentland A (2012) The new science of building great teams. Harv Bus Rev 90:60–69

    Google Scholar 

  22. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16(15):e534–e542

    Article  PubMed  PubMed Central  Google Scholar 

  23. Sidhom MA, Poulsen MG (2006) Multidisciplinary care in oncology: medicolegal implications of group decisions. Lancet Oncol 7(11):951–954

    Article  PubMed  Google Scholar 

  24. Blayney DW (2013) Tumor boards (Team Huddles) aren’t enough to reach the goal. J Natl Cancer Inst 105(2):82–84

    Article  PubMed  Google Scholar 

  25. Taylor C, Ramirez A (2009) Multidisciplinary team member’s views about MDT working: results from a survey commisioned by the National Cancer Action Team. NHS National Cancer Action Team, London

    Google Scholar 

  26. Katterhagen JG, Wishart DL (1977) The tumor board—How it works in a community hospital. CA Cancer J Clin 27(4):201–204

    Article  CAS  PubMed  Google Scholar 

  27. De Ieso PB, Coward JI, Letsa I, Schick U, Nandhabalan M, Fretzas S, Gore ME (2013) A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology. Br J Cancer 109(9):2295–2300

    Article  PubMed  PubMed Central  Google Scholar 

  28. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavanee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820

    Article  PubMed  Google Scholar 

  29. Fleissig A, Jenkins V, Catt S, Fallowfield L (2006) Multidisciplinary teams in cancer care: are they effective in the UK? Lancet Oncol 7(11):935–943

    Article  PubMed  Google Scholar 

Download references

Funding

Financial support came from the Department of Neurosurgery and the Hermelin Brain Tumor Center, Henry Ford Health System.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA

    James Snyder, Lonni Schultz & Tobias Walbert

  2. Department of Public Health Sciences, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA

    Lonni Schultz

  3. Department of Neurology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA

    James Snyder, Lonni Schultz & Tobias Walbert

Authors
  1. James Snyder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lonni Schultz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tobias Walbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias Walbert.

Ethics declarations

Conflict of interest

Dr. Walbert serves on the advisory board of Novocure.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Snyder, J., Schultz, L. & Walbert, T. The role of tumor board conferences in neuro-oncology: a nationwide provider survey. J Neurooncol 133, 1–7 (2017). https://doi.org/10.1007/s11060-017-2416-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-017-2416-x

Keywords

Search

Navigation